160 related articles for article (PubMed ID: 9264346)
1. Low-molecular-weight heparin in the management of Trousseau's syndrome.
Walsh-McMonagle D; Green D
Cancer; 1997 Aug; 80(4):649-55. PubMed ID: 9264346
[TBL] [Abstract][Full Text] [Related]
2. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Couturaud F; Julian JA; Kearon C
Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
[TBL] [Abstract][Full Text] [Related]
4. Continuous subcutaneous heparin infusion for treatment of Trousseau's syndrome.
Alderman CP; McClure AF; Jersmann HP; Scott SD
Ann Pharmacother; 1995; 29(7-8):710-3. PubMed ID: 8520087
[TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.
Mismetti P; Mille D; Laporte S; Charlet V; Buchmüller-Cordier A; Jacquin JP; Fournel P; Dutrey-Dupagne C; Decousus H;
Haematologica; 2003 Jan; 88(1):67-73. PubMed ID: 12551829
[TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism and cancer: prevention and therapy.
Lee AY
Vnitr Lek; 2006 Mar; 52 Suppl 1():127-8, 130-1. PubMed ID: 16637461
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulants and cancer survival.
Piccioli A; Falanga A; Prandoni P
Semin Thromb Hemost; 2006 Nov; 32(8):810-3. PubMed ID: 17171594
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
Lee AY; Rickles FR; Julian JA; Gent M; Baker RI; Bowden C; Kakkar AK; Prins M; Levine MN
J Clin Oncol; 2005 Apr; 23(10):2123-9. PubMed ID: 15699480
[TBL] [Abstract][Full Text] [Related]
10. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients.
Prandoni P; Villalta S; Bagatella P; Rossi L; Marchiori A; Piccioli A; Bernardi E; Girolami B; Simioni P; Girolami A
Haematologica; 1997; 82(4):423-8. PubMed ID: 9299855
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
Nishioka J; Goodin S
J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study on the use of a low-molecular-weight heparin for thromboembolism prophylaxis in large-volume liposuction and body contouring procedures.
Newall G; Ruiz-Razura A; Mentz HA; Patronella CK; Ibarra FR; Zarak A
Aesthetic Plast Surg; 2006; 30(1):86-95; discussion 96-7. PubMed ID: 16404651
[TBL] [Abstract][Full Text] [Related]
13. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
14. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
Huse DM; Cummins G; Taylor DC; Russell MW
Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism in cancer patients: expanding horizons.
Bergqvist D
Semin Thromb Hemost; 2002 Aug; 28 Suppl 3():19-23. PubMed ID: 12232819
[TBL] [Abstract][Full Text] [Related]
16. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.
Kleber FX; Witt C; Vogel G; Koppenhagen K; Schomaker U; Flosbach CW;
Am Heart J; 2003 Apr; 145(4):614-21. PubMed ID: 12679756
[TBL] [Abstract][Full Text] [Related]
18. The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients.
Noble SI; Hood K; Finlay IG
Palliat Med; 2007 Sep; 21(6):473-6. PubMed ID: 17846086
[TBL] [Abstract][Full Text] [Related]
19. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
20. Postoperative anticoagulation in vascular surgery: part 1. A retrospective comparison of clinical outcomes for unfractionated heparin versus low-molecular-weight heparin.
Gramse CA; Hingorani A; Ascher E
J Vasc Nurs; 2001 Jun; 19(2):42-9; quiz 50-1. PubMed ID: 11395717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
